Inogen | INGN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 9.21B 17M 2025-12
Accuray USD 37.18M 567K 2024-12
AngioDynamics USD 81.95M 1.68M 2025-09
Artivion USD 111.2M 9.45M 2025-12
AtriCure USD 138.01M 3.95M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Becton, Dickinson and Co. USD 4.59B 476M 2025-12
Boston Scientific USD 4.04B 18M 2025-12
Chart Industries USD 923.1M 10.3M 2025-09
Cooper Companies USD 811.3M 113.5M 2025-12
Dexcom USD 936.6M 30.2M 2025-12
Edwards Lifesciences USD 1.2B 71.3M 2025-12
Globus Medical USD 645.11M 241.46M 2025-12
Inogen USD 49.14M 665K 2024-09
Insulet USD 637.5M 48.9M 2025-12
Masimo USD 328.6M 181.6M 2025-12
Medtronic USD 7.28B 16M 2025-12
Orthofix International USD 213.79M 12.36M 2025-12
Philips EUR 4.38B 405M 2025-12
ResMed USD 925.21M 51.98M 2025-12
Steris USD 1.22B 28.8M 2025-12
Stryker USD 5.2B 505M 2025-12
Tandem Diabetes Care USD 282.09M 9.97M 2025-12
Teleflex USD 532.64M 3.29B 2025-12
X T L Biopharmaceuticals USD 1.1M 175K 2024-12
Zimmer Biomet Holdings USD 1.94B 277.8M 2025-12